tiprankstipranks
The Fly

Halozyme sees FY24 non-GAAP EPS $3.65-$4.05, consensus $3.99

Halozyme sees FY24 non-GAAP EPS $3.65-$4.05, consensus $3.99

Sees FY24 revenue $935M-$1.015B, consensus $989.87M. FY24 revenue guidance represents a growth of 13%-22% over 2023 total revenue primarily driven by increases in royalty revenue, collaboration revenue and growth in product sales from XYOSTED. Sees FY24 revenue from royalties of $520M-$555M, representing growth of 16% to 24% over 2023. Sees FY24 Adjusted EBITDA $555M-$615M, representing growth of 30% to 44% over 2023.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Questions or Comments about the article? Write to editor@tipranks.com